BioSpace News Archive

ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the Equipment Commissioning and Qualification (C&Q) process (validation life cycle) at Biocon Biologics has been digitized leveraging the power of ValGenesis VLMS – the industry’s most trusted electronic validat

Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman ,today announced the formation of Anteris Bio, a portfolio company developing a new therapy for the treatment of renal disease.

Switch Health, a Canadian healthcare company and industry leader in testing solutions, is pleased to announce Health Canada authorization for the company’s COVID-19 at-home specimen collection kits.

Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed a capital raising of $25,000,410 . Dr Alan Taylor , Executive Chairman of Clarity Pharmaceuticals, commented, “It has been a pivotal year for Clarity with numerous critical m

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced dosing of the first subjects in its Phase 1b clinical trial of Voriconazole Inhalation Powder, a next-generation, direct-to-lung, inhaled dry powder version of voriconazole (NCT #04576325)

New algorithmic module provides automated expert-level assessment of heart function for point-of-care medical teams enabling a quick and reliable detection of cardiac illness and heart attacks

Ultivue announces the addition of two new executive team members in order to help strengthen its position as a leading assay development solutions provider for multiplex biomarker analysis

Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) may occur in up to one-third of COVID-19 patients requiring ICU admission and is a contributing cause of mortality Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS Opaganib has also been shown to inhibit SARS-CoV-2 viral replication as well as pro-inflammatory markers in relevant preclinical models

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers. The new cl

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich as Head of Regulatory, effective December 14, 2020.